Drawing for SPLENDRIS

USPTO serial 79136686

SPLENDRIS

Reviewed by CopyMark Law Group

Reg. 4642937Status 404
Filing date
Status date
Registration date
Nov 25, 2014
Examiner
COLEMAN, NICHOLAS A
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with SPLENDRIS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Timothy T. Wang

TIMOTHY T. WANG Ni, Wang & Massand, PLLC8140 Walnut Hill Lane, Suite 500Dallas, TX 75231UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Chemico-pharmaceutical preparations, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases; Chemical preparations for pharmaceutical purposes, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Medicines for human purposes, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Medicated troches, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system, and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Active pharmaceutical ingredients in the nature of pharmaceutical preparations, which are used for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system, and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Prepared Chinese medicines, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Biochemical medicines, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Dietetic substances adapted for medical use, namely, beverages or food in the nature of vitamin, protein, minerals, lecithin, glucose, amino acid, folic acid, fruit juice, fruit oil, honey, seaweed glue, fish oil, cod-liver oil, cubilose, and mineral food-supplements, which are used for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Drugs for medical purposes, namely, medicines for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system, and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disordersSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 26, 2023DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
Nov 26, 2023DETHDEATH OF INTERNATIONAL REGISTRATION—
Jul 11, 2022INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Jun 9, 2022XXSSGENERIC MADRID TRANSACTION SENT TO IB—
Jun 8, 2022XXCRGENERIC MADRID TRANSACTION CREATED—
Feb 11, 2022INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Jun 11, 2021C71TCANCELLED SECTION 71—
Nov 25, 2019REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Oct 9, 2019CORNCORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED—
Jul 5, 2019CRCVCORRECTION TRANSACTION RECEIVED FROM IB—
Jul 4, 2019NREPNEW REPRESENTATIVE AT IB RECEIVED—
Dec 7, 2018NREPNEW REPRESENTATIVE AT IB RECEIVED—
May 8, 2015FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Apr 20, 2015FICSFINAL DISPOSITION NOTICE SENT TO IB—
Apr 20, 2015FIMPFINAL DISPOSITION PROCESSED—
Mar 12, 2015TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Feb 25, 2015FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Nov 25, 2014R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 9, 2014NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 9, 2014PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 20, 2014NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 7, 2014NREPNEW REPRESENTATIVE AT IB RECEIVED—
Aug 5, 2014PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Aug 5, 2014ALIEASSIGNED TO LIE—
Jul 27, 2014CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 27, 2014XAECEXAMINER'S AMENDMENT ENTERED—
Jul 27, 2014GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jul 27, 2014GNEAEXAMINERS AMENDMENT E-MAILED—
Jul 27, 2014CNEAEXAMINERS AMENDMENT -WRITTEN—
Jun 11, 2014TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 11, 2014CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 11, 2014ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Dec 17, 2013CNFRFINAL REFUSAL MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Dec 16, 2013CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Nov 20, 2013TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 20, 2013CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 20, 2013TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 14, 2013RFNTREFUSAL PROCESSED BY IB—
Oct 23, 2013RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Oct 22, 2013RFRRREFUSAL PROCESSED BY MPU—
Oct 21, 2013RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Oct 20, 2013CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 16, 2013MAFRAPPLICATION FILING RECEIPT MAILED—
Oct 13, 2013DOCKASSIGNED TO EXAMINER—
Oct 12, 2013NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 10, 2013REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance